Systematic Review on the Efficacy and Safety of Immune Checkpoint Inhibition in Renal Cell Carcinoma

Abstract

To perform a systematic review of the relevant literature about clinical trials on efficacy and safety of immune checkpoint inhibition, whether it is used alone, in combination or with other targeted therapies in patients with advanced and metastatic renal cell carcinoma (RCC), two team members reviewed the abstracts and selected pertinent articles from the relevant databases. A narrative review of randomized controlled trials was performed and seven randomized controlled trials were identified in this systematic review. In treatment of RCC, nivolumab has superior efficacy and safety compared with second-line everolimus. Combination strategies, especially those combined with anti-VEGF agents presents better efficacy but worse outcomes in term of safety than monotherapy and conventional treatment and might guide treatment choice for patients with RCC.

Keywords::

• efficacy
• immune checkpoint inhibition
• renal cell carcinoma
• safety

Financial & competing interests disclosure

This study was funded by the National Natural Science Foundation of China (31672514 and 31772699) and the Jilin Scientific and Technological Development Program (20170101024JC). The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

No writing assistance was utilized in the production of this manuscript.

Additional information

Funding

This study was funded by the National Natural Science Foundation of China (31672514 and 31772699) and the Jilin Scientific and Technological Development Program (20170101024JC). The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. No writing assistance was utilized in the production of this manuscript.